Quantum-Si: Sell On Weak Prospects And Risk Of Further Dilution

2025-05-22 07:30:00 ET

Summary

• After mistakenly having been picked up as a quantum computing play in late 2024, shares of life sciences company, Quantum-Si, have given back most of their gains in recent months.
• While the company used the hype to replenish its dwindling cash balances, dilution for common shareholders has been substantial.
• Quantum-Si remains years behind its original business plan with an inflection point nowhere in sight. The company continues to burn substantial amounts of cash.
• Commercialization of Quantum-Si's next-generation protein sequencing platform has been impacted by proposed budget cuts and funding caps at the National Institutes of Health ("NIH").
• While the stock might continue to be picked up by the momentum crowd from time to time, due to its (wrong) association with quantum computing, investors should consider using these spikes to sell existing positions and move on.

Quantum-Si - Not A Quantum Computing Company

At the beginning of the year, I initiated coverage of aspiring life sciences company Quantum-Si incorporated ( QSI ) or "Quantum-Si" with a " Sell " rating after an epic momentum rally had lifted the share price by more than 200% within just ten days:

Read the full article on Seeking Alpha

For further details see: